Page 30 - Read Online

Bresnick EH, Osipo C, Wu J, Strack PR, Tonetti DA, Miele L. human diseases: results and hypotheses. Virology 2004;318:1-9.
Crosstalk between PKCalpha and Notch-4 in endocrine-resistant 70. Martini F, Corallini A, Balatti V, Sabbioni S, Pancaldi C, Tognon M.
breast cancer cells. Oncogenesis 2013;2:e60. Simian virus 40 in humans. Infect Agent Cancer 2007;2:13.
54. Pandya K, Meeke K, Clementz AG, Rogowski A, Roberts J, Miele 71. Cutrone R, Lednicky J, Dunn G, Rizzo P, Bocchetta M, Chumakov
L, Albain KS, Osipo C. Targeting both Notch and ErbB-2 signalling K, Minor P, Carbone M. Some oral poliovirus vaccines were
pathways is required for prevention of ErbB-2-positive breast contaminated with infectious SV40 after 1961. Cancer Res
tumour recurrence. Br J Cancer 2011;105:796-806. 2005;65:10273-9.
55. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J 72. Butel JS, Lednicky JA. Cell and molecular biology of simian virus
Med 1971;285:1182-6. 40: implications for human infections and disease. J Natl Cancer
56. Jakobsson L, Bentley K, Gerhardt H. VEGFRs and Notch: a Inst 1999;91:119-34.
dynamic collaboration in vascular patterning. Biochem Soc Trans 73. Jasani B, Cristaudo A, Emri SA, Gazdar AF, Gibbs A, Krynska
2009;37:1233-6. B, Miller C, Mutti L, Radu C, Tognon M, Procopio A. Association of
57. Gu JW, Rizzo P, Pannuti A, Golde T, Osborne B, Miele L. SV40 with human tumours. Semin Cancer Biol 2001;11:49-61.
Notch signals in the endothelium and cancer “stem-like” cells: 74. Butel JS. Patterns of polyomavirus SV40 infections and associated
opportunities for cancer therapy. Vasc Cell 2012;4:7. cancers in humans: a model. Curr Opin Virol 2012;2:508-14.
58. Boareto M, Jolly MK, Ben-Jacob E, Onuchic JN. Jagged mediates 75. Melnick JL. Papova virus group. Science 1962;135:1128-30.
differences in normal and tumor angiogenesis by affecting tip-stalk fate 76. Alwine JC. Evidence for simian virus 40 late transcriptional
decision. Proc Natl Acad Sci U S A 2015;112:E3836-44. control: mixed infections of wild-type simian virus 40 and a late
59. Pedrosa AR, Trindade A, Carvalho C, Graca J, Carvalho S, leader deletion mutant exhibit trans effects on late viral RNA
Peleteiro MC, Adams RH, Duarte A. Endothelial Jagged1 promotes synthesis. J Virol 1982;42:798-803.
solid tumor growth through both pro-angiogenic and angiocrine 77. Hay N, Skolnik-David H, Aloni Y. Attenuation in the control of
functions. Oncotarget 2015;6:24404-23. SV40 gene expression. Cell 1982;29:183-93.
60. Kangsamaksin T, Murtomaki A, Kofler NM, Cuervo H, Chaudhri 78. Ng SC, Mertz JE, Sanden-Will S, Bina M. Simian virus 40
RA, Tattersall IW, Rosenstiel PE, Shawber CJ, Kitajewski J. maturation in cells harboring mutants deleted in the agnogene. J Biol
NOTCH decoys that selectively block DLL/ NOTCH or JAG/ Chem 1985;260:1127-32.
NOTCH disrupt angiogenesis by unique mechanisms to inhibit 79. Sullivan CS, Grundhoff AT, Tevethia S, Pipas JM, Ganem D. SV40-
tumor growth. Cancer Discov 2015;5:182-97. encoded microRNAs regulate viral gene expression and reduce
61. Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, susceptibility to cytotoxic T cells. Nature 2005;435:682-6.
Ivy SP. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem 80. Alwine JC, Khoury G. Simian virus 40-associated small RNA:
cells: clinical update. Nat Rev Clin Oncol 2015;12:445-64. mapping on the simian virus 40 genome and characterization of its
62. Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, synthesis. J Virol 1980;36:701-8.
Tsaparikos K, Jani JP, Hosea N, Sands M, Randolph S, Smeal T. 81. Takemoto KK, Mullarkey MF. Human papovavirus, BK strain:
Evaluation of selective gamma-secretase inhibitor PF-03084014 for biological studies including antigenic relationship to simian virus 40.
its antitumor efficacy and gastrointestinal safety to guide optimal J Virol 1973;12:625-31.
clinical trial design. Mol Cancer Ther 2010;9:1618-28. 82. Walker DL, Padgett BL, Zu Rhein G, Albert A, Marsh R. Current study
63. Smith DC, Eisenberg PD, Manikhas G, Chugh R, Gubens MA, Stagg of an opportunistic papovavirus. In: Zeman W, Lennette EH, editors.
RJ, Kapoun AM, Xu L, Dupont J, Sikic B. A phase I dose Slow Virus Disease. Baltimore: Williams and Wilkins; 1973. p. 49-58.
escalation and expansion study of the anticancer stem cell agent 83. Shah KV, Ozer HL, Ghazey HN, Kelly TJ Jr. Common structural
demcizumab (anti-DLL4) in patients with previously treated solid antigen of papovaviruses of the simian virus 40-polyoma subgroup.
tumors. Clin Cancer Res 2014;20:6295-303. J Virol 1977;21:179-86.
64. Westhoff B, Colaluca IN, D’Ario G, Donzelli M, Tosoni D, Volorio 84. Yang RC, Wu R. BK virus DNA: complete nucleotide sequence
S, Pelosi G, Spaggiari L, Mazzarol G, Viale G, Pece S, Di Fiore PP. of a human tumor virus. Science 1979;206:456-62.
Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci 85. Frisque RJ, Bream GL, Cannella MT. Human polyomavirus JC
U S A 2009;106:22293-8. virus genome. J Virol 1984;51:458-69.
65. Sun W, Gaykalova DA, Ochs MF, Mambo E, Arnaoutakis D, Liu 86. Garcea RL, Imperiale MJ. Simian virus 40 infection of humans.
Y, Loyo M, Agrawal N, Howard J, Li R, Ahn S, Fertig E, Sidransky J Virol 2003;77:5039-45.
D, Houghton J, Buddavarapu K, Sanford T, Choudhary A, Darden 87. Barbanti-Brodano G, Martini F, De Mattei M, Lazzarin L, Corallini
W, Adai A, Latham G, Bishop J, Sharma R, Westra WH, Hennessey A, Tognon M. BK and JC human polyomaviruses and simian
P, Chung CH, Califano JA. Activation of the NOTCH pathway in virus 40: natural history of infection in humans, experimental
head and neck cancer. Cancer Res 2014;74:1091-104. oncogenicity, and association with human tumors. Adv Virus Res
66. Pece S, Serresi M, Santolini E, Capra M, Hulleman E, Galimberti 1998;50:69-99.
V, Zurrida S, Maisonneuve P, Viale G, Di Fiore PP. Loss of negative 88. Imperiale MJ. Oncogenic transformation by the human
regulation by Numb over Notch is relevant to human breast polyomaviruses. Oncogene 2001;20:7917-23.
carcinogenesis. J Cell Biol 2004;167:215-21. 89. Imperiale MJ. The human polyomaviruses: an overview. In: Khalili K,
67. Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Stoner GL, editors. Human Polyomaviruses: molecular and Clinical
Ateeq B, Asangani IA, Iyer M, Maher CA, Grasso CS, Lonigro Perspectives. New York: Wiley-Liss, Inc.; 2001. p. 53-71.
RJ, Quist M, Siddiqui J, Mehra R, Jing X, Giordano TJ, Sabel 90. Hurault de Ligny B, Godin M, Lobbedez T, El Haggan W, Pujo M,
MS, Kleer CG, Palanisamy N, Natrajan R, Lambros MB, Reis- Etienne I, Ryckelynck JP. Virological, epidemiological and pathogenic
Filho JS, Kumar-Sinha C, Chinnaiyan AM. Functionally recurrent aspects of human polyomaviruses. Presse Med 2003;32:656-8.
rearrangements of the MAST kinase and Notch gene families in 91. Pipas JM, Levine AJ. Role of T antigen interactions with p53 in
breast cancer. Nat Med 2011;17:1646-51. tumorigenesis. Semin Cancer Biol 2001;11:23-30.
68. Sweet BH, Hilleman MR. The vacuolating virus, S.V. 40. Proc Soc 92. Saenz-Robles MT, Sullivan CS, Pipas JM. Transforming functions
Exp Biol Med 1960;105:420-7. of simian virus 40. Oncogene 2001;20:7899-907.
69. Barbanti-Brodano G, Sabbioni S, Martini F, Negrini M, Corallini A, 93. Dyson N, Bernards R, Friend SH, Gooding LR, Hassell JA, Major
Tognon M. Simian virus 40 infection in humans and association with EO, Pipas JM, Vandyke T, Harlow E. Large T antigens of many

20
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ Issue 1 ¦ January 15, 2016 ¦